Trial · NCT01282632
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Hamilton Depression Rating Scale at 1 week | day one | Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 1 week | day one | MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 1 week | day one | Impact on anxiety will be measured by the HAM-A over the 6 weeks. |
| Primary | Change from Baseline in Hamilton Depression Rating Scale at 2 weeks | day 8 | Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Hamilton Depression Rating Scale at 3 weeks | day 15 | Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Hamilton Depression Rating Scale at 4 weeks | day 22 | Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Hamilton Depression Rating Scale at 5 weeks | day 29 | Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Hamilton Depression Rating Scale at 6 weeks | day 43 | Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 2 weeks | day 8 | MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 3 weeks | day 15 | MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 4 weeks | day 22 | MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 5 weeks | day 29 | MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 6 weeks | day 43 | MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6. |
| Primary | Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 2 weeks | day 8 | Impact on anxiety will be measured by the HAM-A over the 6 weeks. |
| Primary | Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 3 weeks | day 15 | Impact on anxiety will be measured by the HAM-A over the 6 weeks. |
| Primary | Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 4 weeks | day 15 | Impact on anxiety will be measured by the HAM-A over the 6 weeks. |
| Primary | Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 5 weeks | day 22 | Impact on anxiety will be measured by the HAM-A over the 6 weeks. |
| Primary | Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 6 weeks | day 43 | Impact on anxiety will be measured by the HAM-A over the 6 weeks. |
| Secondary | Clinical Global Improvement Scale - Improvement | day one | Subjects currently taking a SSRI or a SNRI for at least 4 weeks, at adequate dosage and not responding, as defined by a score of 3 or more on the CGI-I. |
| Secondary | Change from Baseline of Weight at 6 weeks | day 43 | Weight (Kg) will be measured with subjects at screening then at week 6. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01282632/registered